Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) had its price target decreased by stock analysts at Chardan Capital from $5.50 to $4.00 in a research note issued on Thursday. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target would indicate a potential upside of 257.14% from the company’s current price.

Separately, ValuEngine downgraded Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

Shares of Aralez Pharmaceuticals (NASDAQ ARLZ) opened at 1.12 on Thursday. The stock’s market capitalization is $73.75 million. The company’s 50 day moving average price is $1.32 and its 200 day moving average price is $2.17. Aralez Pharmaceuticals has a one year low of $1.09 and a one year high of $6.80.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.01. The company had revenue of $27.62 million for the quarter, compared to the consensus estimate of $21.37 million. Aralez Pharmaceuticals had a negative return on equity of 66.74% and a negative net margin of 133.92%. The business’s revenue was up 119.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.27) EPS. On average, equities analysts expect that Aralez Pharmaceuticals will post ($1.56) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/10/chardan-capital-lowers-aralez-pharmaceuticals-inc-nasdaqarlz-price-target-to-4-00.html.

In other Aralez Pharmaceuticals news, Director Arthur S. Kirsch bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average price of $1.17 per share, for a total transaction of $58,500.00. Following the purchase, the director now directly owns 206,609 shares in the company, valued at $241,732.53. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jason Aryeh sold 388,685 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $1.44, for a total value of $559,706.40. Following the sale, the director now owns 15,000 shares of the company’s stock, valued at approximately $21,600. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 569,115 shares of company stock valued at $790,719. 6.70% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in ARLZ. Goldman Sachs Group Inc. increased its stake in shares of Aralez Pharmaceuticals by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock valued at $260,000 after buying an additional 354 shares during the last quarter. FNY Managed Accounts LLC increased its stake in shares of Aralez Pharmaceuticals by 4.2% in the first quarter. FNY Managed Accounts LLC now owns 77,119 shares of the company’s stock valued at $165,000 after buying an additional 3,136 shares during the last quarter. Salzhauer Michael increased its stake in shares of Aralez Pharmaceuticals by 4.5% in the second quarter. Salzhauer Michael now owns 106,293 shares of the company’s stock valued at $144,000 after buying an additional 4,600 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Aralez Pharmaceuticals by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 314,224 shares of the company’s stock valued at $1,386,000 after buying an additional 7,014 shares during the last quarter. Finally, Isthmus Partners LLC increased its stake in shares of Aralez Pharmaceuticals by 4.9% in the first quarter. Isthmus Partners LLC now owns 153,102 shares of the company’s stock valued at $328,000 after buying an additional 7,110 shares during the last quarter. Hedge funds and other institutional investors own 35.61% of the company’s stock.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Stock Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.